floxuridine has been researched along with Hepatocellular Carcinoma in 71 studies
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To conduct a pilot trial of hepatic arterial infusion (HAI) of floxuridine (FUDR), leucovorin, Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), and cisplatin (FLAP) in nonresectable hepatocellular cancer (HCC) confined to the liver and assess the effects of hepatitis B (HBV) and hepatitis C (HCV) viral markers on toxicity, response to treatment, and patient survival." | 9.07 | Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: effects of hepatitis B and C viral infection on drug toxicity and patient survival. ( Carrasco, H; Charnsangavej, C; Chase, J; Chuang, V; Fischer, H; Lawrence, D; Patt, YZ; Roh, M; Smith, R; Yoffe, B, 1994) |
| "We report a series of novel O-(substituted benzyl) phosphoramidate prodrugs of 5-fluoro-2'-deoxyuridine for the treatment of hepatocellular carcinoma." | 7.83 | Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2'-Deoxyuridine for the Treatment of Hepatocellular Carcinoma. ( Chang, J; Jiang, J; Kang, J; Li, E; Li, L; Liu, B; Peng, Y; Wang, Q; Wang, Y; Wu, J; Yang, Q; Yu, W; Zhang, J, 2016) |
| "Doxifluridine is an oral fluoropyrimidine derivative activated to 5-fluorouracil by uridine phosphorylase which is more expressed in malignant cells." | 6.69 | Oral doxifluridine in advanced hepatocellular carcinoma: A phase II study. ( Allegrini, G; Bartolozzi, C; Brunetti, I; Conte, PF; Di Marsico, R; Falcone, A; Fontana, E; Lencioni, M; Masi, G; Orlandini, C; Pfanner, E; Stampino, CG, 2000) |
| "Thirty-nine patients with hepatocellular carcinoma were treated with oral 5'-DFUR for more than 4 d before operation." | 5.33 | 5-Fluorouracil concentration in blood, liver and tumor tissues and apoptosis of tumor cells after preoperative oral 5'-deoxy-5-fluorouridine in patients with hepatocellular carcinoma. ( Wang, HD; Zheng, JF, 2005) |
| "This study reports the results of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (dex) in patients with unresectable intrahepatic cholangiocarcinoma (ICC) or hepatocellular carcinoma (HCC) and investigates dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) assessment of tumor vascularity as a biomarker of outcome." | 5.14 | Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. ( Blumgart, LH; D'Angelica, M; DeMatteo, R; Fong, Y; Gönen, M; Gultekin, DH; Haviland, D; Jarnagin, WR; Kemeny, N; Schwartz, LH; Shia, J; Tse, A, 2009) |
| "The results suggest that, compared with historical controls, high-dose focal liver irradiation with hepatic artery floxuridine prolongs survival in patients with unresectable chemotherapy-refractory metastatic colorectal cancer and primary hepatobiliary tumors." | 5.11 | Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. ( Ben-Josef, E; Dawson, LA; Ensminger, WD; Knol, J; Lawrence, TS; Normolle, D; Pan, C; Tatro, D; Ten Haken, RK; Walker, S, 2005) |
| "To conduct a pilot trial of hepatic arterial infusion (HAI) of floxuridine (FUDR), leucovorin, Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), and cisplatin (FLAP) in nonresectable hepatocellular cancer (HCC) confined to the liver and assess the effects of hepatitis B (HBV) and hepatitis C (HCV) viral markers on toxicity, response to treatment, and patient survival." | 5.07 | Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: effects of hepatitis B and C viral infection on drug toxicity and patient survival. ( Carrasco, H; Charnsangavej, C; Chase, J; Chuang, V; Fischer, H; Lawrence, D; Patt, YZ; Roh, M; Smith, R; Yoffe, B, 1994) |
| "We report a series of novel O-(substituted benzyl) phosphoramidate prodrugs of 5-fluoro-2'-deoxyuridine for the treatment of hepatocellular carcinoma." | 3.83 | Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2'-Deoxyuridine for the Treatment of Hepatocellular Carcinoma. ( Chang, J; Jiang, J; Kang, J; Li, E; Li, L; Liu, B; Peng, Y; Wang, Q; Wang, Y; Wu, J; Yang, Q; Yu, W; Zhang, J, 2016) |
| "To investigate the efficacy of hepatic arterial infusion chemotherapy (HAIC) using floxuridine (FUDR) in patients with advanced hepatocellular carcinoma (HCC) confined to the liver." | 3.78 | Efficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma. ( Baek, YH; Cho, JH; Choi, YM; Han, SY; Jeong, JS; Kim, KT; Kim, YH; Lee, HS; Lee, SW; Nam, KJ; Park, BH; Roh, YH, 2012) |
| "The action of floxuridine depends greatly on its concentration for treatment of liver metastases of colorectal carcinomas and other tumors." | 3.66 | [Completely implantable infusion pump. A new therapeutic possibility for selected patients with liver tumors]. ( Balch, CM; Urist, MM, 1983) |
| "Patients with unresectable intrahepatic cholangiocarcinoma (ICC) or hepatocellular carcinoma (HCC) were treated with HAI FUDR/Dex plus IV Bev." | 2.76 | Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? ( Allen, P; D'Angelica, MI; Fong, Y; Gewirtz, AN; Gönen, M; Gultekin, D; Haviland, D; Jarnagin, WR; Kemeny, NE; Schwartz, L; Yopp, A, 2011) |
| "Doxifluridine is an oral fluoropyrimidine derivative activated to 5-fluorouracil by uridine phosphorylase which is more expressed in malignant cells." | 2.69 | Oral doxifluridine in advanced hepatocellular carcinoma: A phase II study. ( Allegrini, G; Bartolozzi, C; Brunetti, I; Conte, PF; Di Marsico, R; Falcone, A; Fontana, E; Lencioni, M; Masi, G; Orlandini, C; Pfanner, E; Stampino, CG, 2000) |
| "In all three studies, the incidence of hyperbilirubinemia and biliary stent placement within 1 year of treatment was increased with the addition of Bev." | 1.40 | Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab. ( Allen, P; Capanu, M; Cercek, A; D'Angelica, M; DeMatteo, RP; Fong, Y; Gewirtz, A; Jarnagin, WR; Kemeny, NE; Patel, D; Power, D, 2014) |
| "To establish a multidrug-resistant hepatocellular carcinoma cell line BEL-7402/5-deoxy-5-fluorouridine (5'-DFUR) and study the mechanisms of the drug resistance." | 1.35 | [Establishment of a 5-DFUR-resistant human hepatocellular carcinoma cell model and preliminary study of the mechanisms of the drug resistance]. ( Li, RP; Liang, P; Tang, H, 2008) |
| "Thirty-nine patients with hepatocellular carcinoma were treated with oral 5'-DFUR for more than 4 d before operation." | 1.33 | 5-Fluorouracil concentration in blood, liver and tumor tissues and apoptosis of tumor cells after preoperative oral 5'-deoxy-5-fluorouridine in patients with hepatocellular carcinoma. ( Wang, HD; Zheng, JF, 2005) |
| "A total of 22 patients (11 with hepatocellular carcinoma and 11 with cholangiocarcinoma) were treated." | 1.30 | Long-term results of hepatic artery fluorodeoxyuridine and conformal radiation therapy for primary hepatobiliary cancers. ( Andrews, JC; Ensminger, WD; Kessler, ML; Lawrence, TS; Robertson, JM; Walker, S, 1997) |
| "A 65-year-old female patient with liver cirrhosis complicated with hepatocellular carcinoma (HCC) was treated with oral administration of 5'-DFUR (600 mg/day)." | 1.29 | [A case of hepatocellular carcinoma responding to oral administration of 5'-DFUR]. ( Mizuno, M; Ogino, M; Tanaka, Y; Tokuda, H; Yamauchi, M, 1996) |
| "Twelve of the patients had primary hepatocellular carcinoma and six had metastatic liver carcinoma originating from an unknown primary site." | 1.27 | Hepatic arterial chemotherapy and occlusion for palliation of primary hepatocellular and unknown primary neoplasms in the liver. ( Benjamin, RS; Chuang, VP; Fuqua, R; Mavligit, GM; Patt, YZ; Wallace, S, 1983) |
| "Three patients with primary hepatocellular carcinoma demonstrated less than 50% reduction in tumor size." | 1.27 | Assessment of treatment of intrahepatic malignancies using chemotherapy via an implantable pump. ( Jones, LS; McCune, CS; Schwartz, SI, 1985) |
| "Of 13 patients with hepatoma, nine had clinically significant regression with a median survival of 11 months." | 1.26 | The practicality of chronic hepatic artery infusion therapy of primary and metastatic hepatic malignancies: ten-year results of 124 patients in a prospective protocol. ( Al-Sarraf, M; Baker, L; Izbicki, R; Reed, ML; Sexon-Porte, M; Singhakowinta, A; Straatsma, GW; Vaitkevicius, VK; Vaughn, CB, 1981) |
| "Although advanced gastrointestinal cancer is the most commonplace problem encountered by the medical oncologist, this group of diseases has proved exceedingly resistant to past chemotherapy efforts." | 1.25 | Clinical management of advanced gastrointestinal cancer. ( Moertel, CG, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 37 (52.11) | 18.7374 |
| 1990's | 13 (18.31) | 18.2507 |
| 2000's | 11 (15.49) | 29.6817 |
| 2010's | 8 (11.27) | 24.3611 |
| 2020's | 2 (2.82) | 2.80 |
| Authors | Studies |
|---|---|
| Peng, Y | 1 |
| Yu, W | 1 |
| Li, E | 1 |
| Kang, J | 1 |
| Wang, Y | 1 |
| Yang, Q | 1 |
| Liu, B | 1 |
| Zhang, J | 2 |
| Li, L | 1 |
| Wu, J | 1 |
| Jiang, J | 1 |
| Wang, Q | 1 |
| Chang, J | 1 |
| Rico, L | 1 |
| Østergaard, ME | 1 |
| Bell, M | 1 |
| Seth, PP | 1 |
| Hanessian, S | 1 |
| Peng, X | 1 |
| Gao, J | 1 |
| Yuan, Y | 1 |
| Liu, H | 1 |
| Lei, W | 1 |
| Li, S | 1 |
| Wang, S | 2 |
| Xue, F | 1 |
| Lin, X | 2 |
| Cai, Z | 1 |
| Liu, X | 1 |
| Ma, Y | 1 |
| Wu, M | 1 |
| Zhang, H | 1 |
| Xu, H | 1 |
| Tang, Q | 1 |
| Bi, F | 1 |
| Cercek, A | 1 |
| D'Angelica, M | 2 |
| Power, D | 1 |
| Capanu, M | 1 |
| Gewirtz, A | 1 |
| Patel, D | 1 |
| Allen, P | 2 |
| Fong, Y | 3 |
| DeMatteo, RP | 1 |
| Jarnagin, WR | 3 |
| Kemeny, NE | 2 |
| Zhao, C | 1 |
| Wang, XJ | 1 |
| Feng, WH | 1 |
| Shi, L | 1 |
| Yu, CP | 1 |
| Tang, H | 1 |
| Liang, P | 1 |
| Li, RP | 1 |
| Schwartz, LH | 1 |
| Gultekin, DH | 1 |
| Gönen, M | 2 |
| Haviland, D | 2 |
| Shia, J | 1 |
| DeMatteo, R | 1 |
| Tse, A | 1 |
| Blumgart, LH | 1 |
| Kemeny, N | 1 |
| Schwartz, L | 1 |
| Yopp, A | 1 |
| Gultekin, D | 1 |
| D'Angelica, MI | 1 |
| Gewirtz, AN | 1 |
| Baek, YH | 1 |
| Kim, KT | 1 |
| Lee, SW | 1 |
| Jeong, JS | 1 |
| Park, BH | 1 |
| Nam, KJ | 1 |
| Cho, JH | 1 |
| Kim, YH | 1 |
| Roh, YH | 1 |
| Lee, HS | 1 |
| Choi, YM | 1 |
| Han, SY | 1 |
| Wang, J | 1 |
| Yin, C | 1 |
| Tang, G | 1 |
| Wu, Q | 1 |
| Feun, LG | 1 |
| O'Brien, C | 1 |
| Molina, E | 1 |
| Rodriguez, M | 1 |
| Jeffers, L | 1 |
| Schiff, ER | 1 |
| Marini, A | 1 |
| Savaraj, N | 1 |
| Ardalan, B | 1 |
| MORSE, PA | 1 |
| POTTER, VR | 1 |
| Elias, D | 1 |
| de Baere, T | 1 |
| Sideris, L | 1 |
| Ducreux, M | 1 |
| Zhou, J | 1 |
| Xiao, YS | 1 |
| Tang, ZY | 1 |
| Fan, J | 1 |
| Wu, ZQ | 1 |
| Zhao, Y | 1 |
| Xue, Q | 1 |
| Shen, ZZ | 1 |
| Liu, YK | 1 |
| Ye, SL | 1 |
| Zheng, JF | 1 |
| Wang, HD | 1 |
| Ben-Josef, E | 1 |
| Normolle, D | 2 |
| Ensminger, WD | 3 |
| Walker, S | 3 |
| Tatro, D | 1 |
| Ten Haken, RK | 2 |
| Knol, J | 1 |
| Dawson, LA | 2 |
| Pan, C | 1 |
| Lawrence, TS | 4 |
| Hao, MZ | 1 |
| Lin, HL | 1 |
| Chen, Q | 1 |
| Wu, H | 1 |
| Yu, WC | 1 |
| Chen, TG | 1 |
| Balch, CM | 2 |
| Urist, MM | 2 |
| Patt, YZ | 2 |
| Chuang, VP | 1 |
| Wallace, S | 2 |
| Benjamin, RS | 1 |
| Fuqua, R | 1 |
| Mavligit, GM | 1 |
| Reed, ML | 1 |
| Vaitkevicius, VK | 1 |
| Al-Sarraf, M | 1 |
| Vaughn, CB | 1 |
| Singhakowinta, A | 1 |
| Sexon-Porte, M | 1 |
| Izbicki, R | 1 |
| Baker, L | 1 |
| Straatsma, GW | 1 |
| Niederhuber, JE | 2 |
| Friedman, MA | 1 |
| Curley, SA | 1 |
| Wada, M | 1 |
| Jin, H | 1 |
| Kinugasa, A | 1 |
| Shintani, S | 1 |
| Sawada, K | 1 |
| Yamashita, M | 1 |
| Yamamura, M | 1 |
| Nishigami, T | 1 |
| Kano, M | 1 |
| Shimoyama, T | 1 |
| Miyazaki, K | 1 |
| Yakushiji, H | 1 |
| Kitahara, K | 1 |
| Mori, M | 1 |
| Sasatomi, E | 1 |
| Tsutsumi, N | 1 |
| Hirohashi, Y | 1 |
| Iwanaga, A | 1 |
| Iyama, A | 1 |
| Fukagawa, H | 1 |
| Charnsangavej, C | 2 |
| Yoffe, B | 1 |
| Smith, R | 1 |
| Lawrence, D | 1 |
| Chuang, V | 1 |
| Carrasco, H | 1 |
| Roh, M | 1 |
| Chase, J | 1 |
| Fischer, H | 1 |
| Kessler, ML | 2 |
| Robertson, JM | 2 |
| Campbell, KA | 1 |
| Burns, RC | 1 |
| Sitzmann, JV | 1 |
| Lipsett, PA | 1 |
| Grochow, LB | 1 |
| Tanaka, Y | 1 |
| Ogino, M | 1 |
| Tokuda, H | 1 |
| Mizuno, M | 1 |
| Yamauchi, M | 1 |
| Andrews, JC | 1 |
| Ikeda, K | 1 |
| Saitoh, S | 1 |
| Suzuki, Y | 1 |
| Koida, I | 1 |
| Tsubota, A | 1 |
| Kobayashi, M | 1 |
| Arase, Y | 1 |
| Chayama, K | 1 |
| Murashima, N | 1 |
| Kumada, H | 1 |
| Merle, P | 1 |
| Trepo, C | 1 |
| Port, R | 1 |
| Hanisch, F | 1 |
| Becker, M | 1 |
| Bachert, P | 1 |
| Zeller, J | 1 |
| McGinn, CJ | 1 |
| Ensminger, W | 1 |
| Lencioni, M | 1 |
| Falcone, A | 1 |
| Allegrini, G | 1 |
| Pfanner, E | 1 |
| Masi, G | 1 |
| Brunetti, I | 1 |
| Di Marsico, R | 1 |
| Fontana, E | 1 |
| Orlandini, C | 1 |
| Stampino, CG | 1 |
| Bartolozzi, C | 1 |
| Conte, PF | 1 |
| Clavien, PA | 1 |
| Selzner, N | 1 |
| Morse, M | 1 |
| Selzner, M | 1 |
| Paulson, E | 1 |
| Oberfield, RA | 3 |
| Moertel, CG | 1 |
| Wilkinson, DS | 2 |
| Tlsty, TD | 1 |
| Hanas, RJ | 1 |
| Jackson, RC | 1 |
| Weber, G | 1 |
| Solomonson, LP | 1 |
| Cory, JG | 1 |
| Ryan, R | 1 |
| Metman, EH | 1 |
| Oberfield, R | 1 |
| Glouse, M | 1 |
| Wellwood, JM | 1 |
| Cady, B | 2 |
| Yamashita, Y | 3 |
| Takahashi, M | 3 |
| Shinzato, J | 1 |
| Bussaka, H | 2 |
| Baba, Y | 1 |
| Oguni, T | 1 |
| Koga, Y | 1 |
| Saito, R | 1 |
| Nanakawa, S | 1 |
| Hatanaka, Y | 1 |
| Sato, N | 1 |
| Nakashima, K | 1 |
| Urata, J | 1 |
| Yoshizumi, K | 1 |
| Strohmeyer, G | 1 |
| Porschen, R | 1 |
| Seeger, J | 1 |
| Woodcock, TM | 1 |
| Blumenreich, MS | 1 |
| Richardson, JD | 1 |
| Shibata, T | 1 |
| Sasaki, Y | 1 |
| Imaoka, S | 1 |
| Wada, H | 1 |
| Nagano, H | 1 |
| Ishikawa, O | 1 |
| Ohigashi, H | 1 |
| Fukuda, I | 1 |
| Kabuto, T | 1 |
| Hiratsuka, M | 1 |
| Fukushima, S | 1 |
| Kawaguchi, T | 1 |
| Nakano, M | 1 |
| Schwartz, SI | 1 |
| Jones, LS | 1 |
| McCune, CS | 1 |
| Carrasco, CH | 1 |
| Richli, W | 1 |
| Haynie, TP | 1 |
| Blachly, RJ | 1 |
| Reid, IS | 1 |
| Hutchins, LF | 1 |
| Lang, NP | 1 |
| Neilan, BA | 1 |
| Ortego, SG | 1 |
| Lai, KH | 1 |
| Tsai, YT | 1 |
| Lee, SD | 1 |
| Yeh, YS | 1 |
| Wang, SS | 1 |
| Ng, WW | 1 |
| Wang, JY | 1 |
| Chiang, TT | 1 |
| Lay, CS | 1 |
| Yang, CF | 1 |
| Bresnick, E | 1 |
| Thompson, UB | 1 |
| Khwaja, TA | 1 |
| Heidelberger, C | 3 |
| Van Dyk, JJ | 1 |
| Clarkson, BD | 1 |
| Duschinsky, R | 1 |
| Keller, O | 1 |
| La Sala, E | 1 |
| Krakoff, IH | 1 |
| Baden, H | 1 |
| Umeda, M | 1 |
| Wolberg, WH | 2 |
| Sanderson, TA | 1 |
| McBride, CM | 1 |
| Bloomenthal, ED | 1 |
| Spellberg, MA | 1 |
| Nesnow, S | 1 |
| Mian, AM | 1 |
| Oki, T | 1 |
| Dexter, DL | 1 |
| Tsou, KC | 1 |
| Ledis, S | 1 |
| McCoy, MG | 1 |
| Norman, EJ | 1 |
| Nagyvary, J | 1 |
| Morgenthaler, FR | 1 |
| Pettavel, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single-Arm Phase II Study of Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver[NCT03366155] | Phase 2 | 40 participants (Anticipated) | Interventional | 2019-06-24 | Recruiting | ||
| Pilot Study of Hepatic Arterial Infusion Therapy in Patients With Unresectable or Borderline Resectable Intrahepatic Cholangiocarcinoma[NCT01525069] | Phase 1 | 27 participants (Actual) | Interventional | 2012-04-03 | Terminated (stopped due to Equipment that was used in the study was discontinued) | ||
| A Phase II Study of Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Bevacizumab (A Monoclonal Antibody to Vascular Endothelial Growth Factor-A), in Patients With Unresectable Primary Hepatic Malignancy[NCT00410956] | Phase 2 | 55 participants (Anticipated) | Interventional | 2007-05-31 | Active, not recruiting | ||
| A Phase 2 Study of Low-Dose Fractionated Radiation Therapy to the Whole Liver in Combination With Gemcitabine and Cisplatin in Locally Advanced Mass-Forming Intrahepatic Cholangiocarcinoma[NCT02254681] | Phase 2 | 6 participants (Actual) | Interventional | 2014-09-30 | Terminated (stopped due to lack of funding) | ||
| A Humanitarian Device Exemption Use Protocol of Therasphere® for Treatment of Unresectable Hepatocellular and Metastatic Liver Tumors - HDE #980006[NCT00701168] | 0 participants | Expanded Access | No longer available | ||||
| Human Liver Explants for HIF-1 Alpha- Analysis/Comparison[NCT00866957] | 180 participants (Actual) | Observational | 2006-02-28 | Completed | |||
| A Phase III Randomized Trial of Standard Dose Stereotactic Body Radiation Therapy (SBRT) Versus Radiobiologically-Guided Dose Selected SBRT In Primary or Secondary Liver Carcinoma (SAVIOR).[NCT04745390] | 110 participants (Anticipated) | Interventional | 2021-08-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To determine the number of participants with Intrahepatic disease progression assessed by MRI of the abdomen with intravenous gadolinium contrast using RECIST criteria. (NCT02254681)
Timeframe: From date of first treatment until date of first documented progression or date of death from any cause, which ever comes first, assessed up to 24 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 6 |
To determine the number of participants with Intrahepatic recurrence assessed by RECIST criteria using MRI of the abdomen with intravenous gadolinium contrast. (NCT02254681)
Timeframe: From date of partial hepatectomy until date of first documented recurrence or date of death from any cause, assessed up to 24 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
Measured post-operative complications include (but not limited to) bile leak, liver failure, ascites, infection, any organ failure or insufficiency, venous thromboembolism, and mortality. (NCT02254681)
Timeframe: up to 90 days after partial hepatectomy
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
5 reviews available for floxuridine and Hepatocellular Carcinoma
| Article | Year |
|---|---|
Regional chemotherapeutic techniques for liver tumors: current knowledge and future directions.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Colorectal Neoplasms; Dose-Response Relationship, | 2004 |
Hepatic intraarterial chemotherapy--current status and future prospects--"If you have a short sword, take a step forward".
Topics: Carcinoma, Hepatocellular; Catheterization; Colonic Neoplasms; Doxorubicin; Floxuridine; Hepatic Art | 1983 |
Update on regional treatments for hepatobiliary malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; | 1995 |
Antiblastic drug targeting to hepatocellular carcinoma cells: a potential therapeutic improvement?
Topics: Amino Sugars; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco | 1998 |
[Interdisciplinary therapy concepts in primary and secondary neoplasms of the liver].
Topics: Carcinoma, Hepatocellular; Combined Modality Therapy; Floxuridine; Fluorouracil; Follow-Up Studies; | 1989 |
12 trials available for floxuridine and Hepatocellular Carcinoma
| Article | Year |
|---|---|
Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bi | 2009 |
Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results?
Topics: Aged; Alkaline Phosphatase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplasti | 2011 |
Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; | 2003 |
Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, In | 2005 |
[Efficacy of transcatheter arterial chemoembolization combined thalidomide on hepatocellular carcinoma: a controlled randomized trial].
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Chemoemboliza | 2007 |
Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: effects of hepatitis B and C viral infection on drug toxicity and patient survival.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubi | 1994 |
A prospective randomized administration of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Combined Moda | 1997 |
Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Colorect | 2000 |
Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Colorect | 2000 |
Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Colorect | 2000 |
Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Colorect | 2000 |
Oral doxifluridine in advanced hepatocellular carcinoma: A phase II study.
Topics: Administration, Oral; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellu | 2000 |
Evaluation of oil-soluble FUdR ester for transcatheter arterial treatment of hepatomas.
Topics: Carcinoma, Hepatocellular; Catheters, Indwelling; Chemoembolization, Therapeutic; Doxorubicin; Drug | 1992 |
Hepatic infusional chemotherapy in metastatic colorectal carcinoma and hepatoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colonic Neoplasms; Female; Floxuri | 1985 |
Clinical trial of doxifluridine in the treatment of primary hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Clinical Trials as Topic; Female; Floxuridine; Humans; Liver Neopla | 1986 |
54 other studies available for floxuridine and Hepatocellular Carcinoma
| Article | Year |
|---|---|
Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2'-Deoxyuridine for the Treatment of Hepatocellular Carcinoma.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Area Under Curve; Carcinoma, Hepatocellular; D | 2016 |
Studies directed toward the asialoglycoprotein receptor mediated delivery of 5-fluoro-2'-deoxyuridine for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Asialoglycoprotein Receptor; Carcinoma, Hepatocellular; Deoxyuridine; Drug De | 2018 |
Hypoxia-Activated and Indomethacin-Mediated Theranostic Prodrug Releasing Drug On-Demand for Tumor Imaging and Therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; | 2019 |
Doxifluridine-based pharmacosomes delivering miR-122 as tumor microenvironments-activated nanoplatforms for synergistic treatment of hepatocellular carcinoma.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Floxuridine; Gene Expres | 2021 |
The selective serotonin reuptake inhibitors enhance the cytotoxicity of sorafenib in hepatocellular carcinoma cells.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Combina | 2021 |
Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bile | 2014 |
Lobaplatin combined floxuridine/pirarubicin-based transcatheter hepatic arterial chemoembolization for unresectable primary hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap | 2014 |
[Establishment of a 5-DFUR-resistant human hepatocellular carcinoma cell model and preliminary study of the mechanisms of the drug resistance].
Topics: Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, | 2008 |
Efficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Dexamethasone; Disease-Free Survival; Female; Floxuridine; Humans; | 2012 |
Glucose-functionalized multidrug-conjugating nanoparticles based on amphiphilic terpolymer with enhanced anti-tumorous cell cytotoxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cytarabine; Drug Carriers | 2013 |
PYRIMIDINE METABOLISM IN TISSUE CULTURE CELLS DERIVED FROM RAT HEPATOMAS. I. SUSPENSION CELL CULTURES DERIVED FROM THE NOVIKOFF HEPATOMA.
Topics: Animals; Carcinoma, Hepatocellular; Cell Culture Techniques; Floxuridine; Fluorouracil; Glycine; Liv | 1965 |
Transfection of thymidine phosphorylase cDNA to human hepatocellular carcinoma cells enhances sensitivity to fluoropyrimidine but augments endothelial cell migration.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Movement; Disea | 2005 |
5-Fluorouracil concentration in blood, liver and tumor tissues and apoptosis of tumor cells after preoperative oral 5'-deoxy-5-fluorouridine in patients with hepatocellular carcinoma.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Female; Floxuridine; Fluorour | 2005 |
[Intra-arterial chemotherapy using an implantable infusion pump in liver metastases of colorectal tumors and hepatomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Colonic Neoplasms; Doxoru | 1984 |
Hepatic arterial chemotherapy and occlusion for palliation of primary hepatocellular and unknown primary neoplasms in the liver.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; | 1983 |
The practicality of chronic hepatic artery infusion therapy of primary and metastatic hepatic malignancies: ten-year results of 124 patients in a prospective protocol.
Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Colonic Neoplasms; Floxuridine; Humans; Infusions, Intra- | 1981 |
[Completely implantable infusion pump. A new therapeutic possibility for selected patients with liver tumors].
Topics: Carcinoma, Hepatocellular; Catheters, Indwelling; Colonic Neoplasms; Floxuridine; Fluorouracil; Hepa | 1983 |
Surgical considerations in the management of hepatic neoplasia.
Topics: Adenoma, Bile Duct; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheterization; Floxuridine; | 1983 |
Simultaneous occurrence of adenomas in stomach, duodenal bulb, and colon: disappearance of gastric and duodenal adenomas during oral administration of 5'-deoxy-5-fluorouridine.
Topics: Adenoma; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Colonic Neoplasms; Duodenal Neoplas | 1994 |
[A comparative study on the serum and tissue 5-FU concentrations in patients with hepatocellular carcinoma after preoperative oral administration of UFT and 5'-DFUR].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepato | 1994 |
Conformal high-dose radiation plus intraarterial floxuridine for hepatic cancer.
Topics: Aged; Carcinoma, Hepatocellular; Combined Modality Therapy; Floxuridine; Humans; Injections, Intra-A | 1993 |
Regional chemotherapy devices: effect of experience and anatomy on complications.
Topics: Adult; Analysis of Variance; Carcinoma, Hepatocellular; Catheters, Indwelling; Colorectal Neoplasms; | 1993 |
[A case of hepatocellular carcinoma responding to oral administration of 5'-DFUR].
Topics: Administration, Oral; Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Fe | 1996 |
Long-term results of hepatic artery fluorodeoxyuridine and conformal radiation therapy for primary hepatobiliary cancers.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcino | 1997 |
Local disposition kinetics of floxuridine after intratumoral and subcutaneous injection as monitored by [19F]-nuclear magnetic resonance spectroscopy in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Delayed-Action Preparations; Fe | 1999 |
Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2002 |
Current status of regional arterial infusion chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Hepatocellular; Carotid Arteries; Catheterization; | 1975 |
Clinical management of advanced gastrointestinal cancer.
Topics: Adenoma, Islet Cell; Carcinoma, Hepatocellular; Carmustine; Colonic Neoplasms; Cytarabine; Drug Ther | 1975 |
The inhibition of ribosomal RNA synthesis and maturation in Novikoff hepatoma cells by 5-fluorouridine.
Topics: Animals; Carcinoma, Hepatocellular; Cells, Cultured; Floxuridine; Fluorouracil; In Vitro Techniques; | 1975 |
Enzyme pattern directed chemotherapy. The effects of combinations of methotrexate, 5-fluorodeoxyuridine and thymidine on rat hepatoma cells in vitro.
Topics: Animals; Carcinoma, Hepatocellular; Cell Division; Cell Line; Depression, Chemical; Floxuridine; Liv | 1976 |
Increased thymidylate synthetase activity in 5-fluorodeoxyuridine-resistant Novikoff hepatoma cells.
Topics: Adenosine Triphosphatases; Carcinoma, Hepatocellular; Cell Line; Drug Resistance; Floxuridine; Liver | 1977 |
[Fluorinated pyrimidines administered by percutaneous arterial perfusion in primary or secondary cancers of the liver].
Topics: Carcinoma, Hepatocellular; Floxuridine; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neopl | 1977 |
Treatment of primary liver cancer: response to regional chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Reg | 1979 |
Prognostic factors in the treatment of hepatocellular carcinoma with transcatheter arterial embolization and arterial infusion.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combine | 1991 |
Hepatic perfusion with FUdR utilizing an implantable system in patients with liver primary cancer or metastatic cancer confined to the liver.
Topics: Adenocarcinoma; Adenoma, Bile Duct; Adult; Aged; Carcinoma, Hepatocellular; Colorectal Neoplasms; Fl | 1989 |
[Selective anticancer effects of intra-arterial infusion of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine (TT82) in hepatocellular carcinoma].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Combined Modality Therapy; Drug Ev | 1989 |
Intraarterial infusion of 5-fluoro-2-deoxyuridine-C8 dissolved in a lymphographic agent in malignant liver tumors. A preliminary report.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Floxuridine; Humans; Infusions, Intra-Arterial; Iodi | 1989 |
Assessment of treatment of intrahepatic malignancies using chemotherapy via an implantable pump.
Topics: Adenoma, Islet Cell; Aged; alpha-Fetoproteins; Carcinoma, Hepatocellular; Catheterization; Catheters | 1985 |
Hepatic arterial flow distribution with hepatic neoplasms: significance in infusion chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul | 1987 |
Properties of deoxythymidine kinase partially purified from animal tumors.
Topics: Adenosine Triphosphate; Animals; Barium; Bromodeoxyuridine; Calcium Chloride; Carcinoma 256, Walker; | 1965 |
Fluorinated pyrimidines. XXIX. Syntheses of 2',3'-dehydro-5-fluoro-2'-deoxyuridine and 2',3'-dideoxy-5-fluorouridine.
Topics: Animals; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Escherichia coli; Floxuridine; HeLa Ce | 1967 |
Clinical evaluation of 5-bromo-5-fluoro-6-methoxy-dihydro-2'-deoxyuridine.
Topics: Adenocarcinoma; Adult; Aged; Animals; Bromodeoxyuridine; Carcinoma; Carcinoma, Hepatocellular; Carci | 1967 |
Infusion of liver tumours.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Regional Perfusion; Floxurid | 1968 |
[Continuous intra-arterial infusion of 5-fluor-2-deoxyuridine in primary and metastatic liver cancer].
Topics: Adenoma, Bile Duct; Adult; Aged; Arteries; Carcinoma, Hepatocellular; Female; Floxuridine; Gastroint | 1968 |
Comparative studies of fluorinated pyrimidines with various cell lines.
Topics: Animals; Carcinoma, Hepatocellular; Culture Techniques; Deoxyuridine; Depression, Chemical; DNA, Neo | 1968 |
Development of resistance of Novikoff hepatoma to 5-fluoro-2'-deoxyuridine.
Topics: Carbon Isotopes; Carcinoma, Hepatocellular; Culture Techniques; DNA, Neoplasm; Floxuridine; Liver Ne | 1970 |
Considerations in the development of a predictive system for cancer chemotherapy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; DNA; Floxuridine; Fluorouracil; Liver N | 1971 |
Experience with hepatic arterial infusions.
Topics: Adult; Aged; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Female; Floxuridine; Fluorouracil; Gall | 1971 |
Therapy for carcinoma of the liver.
Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Angiography; Aspartate Aminotransferases; Carcino | 1971 |
Fluorinated pyrimidines. 41. Syntheses of 5-trifluoromethyl-3'-deoxyuridine and 5-fluoro-3'-deoxyuridine.
Topics: Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Cells, Cultured; Chromatography, Ion Exc | 1972 |
5'-Nucleotide phosphodiesterase isoenzyme pattern in the serum of human hepatoma.
Topics: Adenoma; Carcinoma, Hepatocellular; Electrophoresis, Polyacrylamide Gel; Fetal Proteins; Floxuridine | 1973 |
Arterial infusion chemotherapy of hepatoma.
Topics: Adolescent; Adult; Aged; Carcinoma, Hepatocellular; Catheterization; Child; Female; Floxuridine; Hum | 1974 |
Synthesis of some trinucleoside monophosphates of biological interest.
Topics: Animals; Biodegradation, Environmental; Bromodeoxyuridine; Carcinoma, Hepatocellular; Chromatography | 1974 |
[Combined drug-surgical treatment in primary and secondary liver tumors].
Topics: Carcinoma, Hepatocellular; Drug Therapy, Combination; Floxuridine; Humans; Injections, Intra-Arteria | 1974 |